secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2026-05-29T21:11:12+00:00
Accession:  0001193125-26-248711
Event type: litigation
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination
--------------------------------------------------------------------------------

- NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.
- NMS claims Cardiff failed to correct inventorship to include Dr. Barbara Valsasina on two U.S. patents and failed to use commercially reasonable efforts for onvansertib.
- Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and declaratory judgment that it did not breach the agreement.
- Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.
- Dispute centers on rights to onvansertib, a key pipeline asset; potential impact on development timeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/0001193125-26-248711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000119312526248711/crdf-20260527.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-248711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer